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Purpose: To investigate chemosensitivity with an adenosine triphosphate-based 
chemotherapy response assay in patients with epithelial ovarian or peritoneal cancer 
according to tumor histology, grade, and disease status. Materials and Methods: 
One hundred specimens were collected during primary or secondary debulking 
from 67 patients with primary ovarian cancer, 24 patients with recurrent ovarian 
cancer, 5 patients with primary peritoneal cancer, and 4 patients with recurrent peri-
toneal cancer; samples were collected between August 2006 and June 2009. Tumor 
cells were isolated and cultured for 48 hours in media containing chemotherapy. 
The chemosensitivity index (CI) was calculated as 300 minus the sum of the cell 
death rate at 0.2×, 1×, and 5× drug concentrations, and the CI values were com-
pared. Results: CI values were obtained from 93 of 100 patients. The most active 
agents against primary disease were ifosfamide and paclitaxel. For primary serous 
adenocarcinoma, paclitaxel and irinotecan were the most active, followed by ifos-
famide. For clear cell carcinoma, ifosfamide was the most active, followed by pacl-
itaxel and irinotecan. Although not statistically significant, the CIs of cisplatin, car-
boplatin, paclitaxel, and docetaxel decreased as tumor grade increased. In 14 cases 
of recurrent disease, paclitaxel was the most active, followed by ifosfamide and cis-
platin. Conclusion: Ifosfamide and paclitaxel were the most active drugs for prima-
ry and recurrent disease. Therefore, we recommend further clinical studies to con-
firm the efficacy of paclitaxel, ifosfamide, and cisplatin combination chemotherapy 
for recurrent and primary ovarian cancer.
Key Words:   Adenosine triphosphate, cell death, drug therapy, combination, ovar-
ian cancer
INTRODUCTION
The chemosensitivity test is an in vitro predictive assay for assessing the sensitivi-
ty of cancer cells to various chemotherapeutic agents. Since the development of 
the human tumor stem cell assay by Hamburger and Salmon in the 1970s, various 
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mens for the ATP-CRA were removed as part of the normal 
treatment procedure. The histological types of tumor tissues 
and qualitative and quantitative analyses of cancer cells 
were evaluated by pathologists. 
Individualized tumor response testing using ATP-CRA 
The ATP-CRA was performed as described previously.10,12 
Briefly, fresh tumor specimens were obtained during sur-
gery and transferred to HBSS (Gibco BRL, Rockville, MD, 
USA) transport media. Cell suspensions were prepared en-
zymatically by incubating with dispase (Sigma, St. Louis, 
MO, USA), pronase (Sigma), and DNase (Sigma) at 37°C 
for 12‒16 hours. Isolated cells were separated from tissue 
fragments by passing through a cell strainer (BD Falcon, 
Bedford, MA, USA). Tumor cells were purified using Fi-
coll (1.077 g/mL) density gradient centrifugation to remove 
red blood cells, dead cells, and residual cell debris. If a suf-
ficient amount of cells was isolated, blood-derived normal 
cells were removed using anti-CD45 antibody-conjugated 
magnetic beads (Miltenyi Biotech, Auburn, CA, USA).13 The 
final tumor cell preparation was suspended in Iscove’s Modi-
fied Dulbecco’s Media (IMDM; Gibco BRL) containing 
10% fetal bovine serum (FBS). Separated tumor cells were 
diluted to 2000‒20000 viable cells per 100 μL using IMDM 
containing 10% FBS. Cells were seeded in triplicate in a 
96-well ultra-low attachment microplate (Costar, Cam-
bridge, MA, USA), which restricted the growth of normal 
cells, such as fibroblasts. For treatment groups, 100 μL of 
chemotherapeutic agent was added to cells and cultured for 
48 hours in a 5% CO2 incubator. In the control groups, 100 
μL of IMDM was added to 3‒6 wells without chemothera-
peutic agents. For quality control purposes, a negative con-
trol group of 3‒6 wells with seeding media only (no cells) 
and two positive control groups were included in the culture 
plate. Each positive control group was composed of three 
wells that contained minimal (105 pg ATP) or median (280 
pg ATP) amounts of ATP, as determined from 1000 tumor 
cells harvested from tumor tissues. Treated drug concentra-
tions (TDC) were derived from preliminary experiments, 
which exhibited a scattered distribution of cell death for 
each specimen.14,15 Drugs were used in triplicate at three 
concentrations (0.2×, 1×, and 5× TDC). The 1× TDCs were 
belotecan, 0.11 μg/mL; carboplatin, 12 μg/mL; cisplatin, 2.5 
μg/mL; docetaxel, 3.7 μg/mL; irinotecan, 4.7 μg/mL; gem-
citabine, 16.9 μg/mL; oxaliplatin, 2.9 μg/mL; paclitaxel, 8.5 
μg/mL; ifosfamide, 0.4 μg/mL; and topotecan, 0.0325 μg/
mL. Because ifosfamide requires in vivo hepatic activation, 
chemosensitivity assays have been created to predict chemo-
therapy response. These assays include titrated thymidine in-
corporation, fluorescent cytoprint, the 5-diphenyltetrazolium 
bromide assay, and the differential staining cytotoxicity as-
say.1-5 The adenosine triphosphate (ATP)-based chemothera-
py response assay (ATP-CRA) is a sensitive assay that eval-
uates tumor cell viability by measuring the intracellular ATP 
levels of drug-exposed cells and untreated controls. The ATP-
based chemosensitivity test is reported to have many advan-
tages, such as feasibility, reproducibility, low cost, small pa-
tient sample requirement, and high positive and negative 
predictive values.6-8 The recently developed ATP-CRA ad-
opted new methods, including the use of ultra-low attach-
ment culture plates, to inhibit the growth of normal cells 
and reduce the turnaround time of the test. The ATP-CRA 
has a high success rate in primary culture and requires only 
a small number of cells. In addition, ATP-CRA results cor-
relate well with clinical outcomes in patients with breast or 
lung cancer.9,10 Furthermore, Han, et al.11 report that the 
ATP-CRA has a high sensitivity and a positive predictive 
value, accurately predicting response to chemotherapy in 
ovarian cancer.
The purpose of this study was to investigate chemosensi-
tivity in epithelial ovarian or peritoneal cancer tissues using 
the ATP-CRA according to tumor histology, grade, and dis-
ease status. We selected 10 chemotherapeutic agents, includ-
ing one alkylating agent (ifosfamide), three platinum ana-
logues (cisplatin, carboplatin, and oxaliplatin), two taxanes 
(paclitaxel and docetaxel), three camptothecin analogues 
(topotecan, irinotecan, and belotecan), and gemcitabine. We 
measured the chemosensitivity index (CI) of these agents in 
cancer tissues using the ATP-CRA. The CI and CI rank 
were compared according to histological type, tumor grade, 
and disease status.
MATERIALS AND METHODS
Patients and tumor tissues
One hundred fresh, sterile tumor specimens were collected 
during primary or secondary debulking from 67 patients with 
primary ovarian cancer, 24 patients with recurrent ovarian 
cancer, 5 patients with primary peritoneal cancer, and 4 pa-
tients with recurrent peritoneal cancer. Samples were ob-
tained according to the guidelines of the Institutional Review 
Board of Yonsei University College of Medicine, Seoul, Ko-
rea, between August 2006 and June 2009. All tumor speci-
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CI. To calculate the intra-assay mean coefficient of varia-
tion (CV), luminescence values of each specimen were 
measured 3‒6 times in both negative and positive control 
groups. We determined whether the measured values at 280 
pg of ATP were higher than those at 105 pg of ATP. If mi-
croorganism contamination or an inadequate number of 
cells was discovered, or if the intra-assay mean CV exceed-
ed 30, the test was considered a failure. If measured values 
in the untreated control group were lower than those in the 
positive group (105 pg of ATP), the specimen was consid-
ered to have unacceptable viability.
Statistical analysis
The data were analyzed using parametric and nonparametric 
statistics with SPSS 12.0 (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics were used for quantitative experimen-
tal data. The Mann-Whitney U test was performed for com-
parisons of CIs in primary and recurrent disease. Compari-
son of CI according to histological grade was performed 
with the Kruskal-Wallis test.
RESULTS
 
Patient characteristics are summarized in Table 1. The me-
dian age was 52 years (range, 22‒71 years). There were 72 
patients with primary epithelial ovarian or peritoneal cancer 
and 28 patients with recurrent cancers. Serous adenocarci-
noma was the most common (67.0%), followed by muci-
nous (9.0%) and endometrioid (9.0%) adenocarcinomas. 
Clear cell carcinoma represented 4.0% of cases. Stage III 
disease was present in 44 of 67 patients (65.7%), and stage 
I was in 13 of 67 (19.4%). Stage II and IV disease was in 5 
of 67 (7.5%) and 5 of 67 (7.5%), respectively. The median 
intra-assay mean CV was 5.45 (range: 2.5 periton one pri-
mary ovarian cancer tissue failed to obtain an acceptable 
CV in 1× concentration, and four primary and three recur-
rent cancer tissues produced insufficient cells at all concen-
trations; thus, the CI values were obtained from 67 primary 
and 25 recurrent cases.
The CI according to histological type is shown in Table 
2. The CI of the three platinum analogues (cisplatin, carbo-
platin, and oxaliplatin) did not show statistically significant 
differences among the serous, mucinous, and endometrioid 
adenocarcinoma groups. However, these three platinum an-
alogues showed decreased CI values with marginal statisti-
cal significance in clear cell carcinoma compared with those 
we used the active metabolite 4-hydroxy ifosfamide (NIO-
MECH, Bielefeld, Germany). The untreated control group 
consisted of primary culture cells from each patient that 
were cultured without chemotherapeutic agents, while the 
treated group consisted of primary culture cells cultured 
with each chemotherapeutic agent. At the end of the incu-
bation, the cells were exposed to reagents to measure ATP 
content according to the manufacturer’s instructions (ATP 
Bioluminescence assay kit HS II, Roche, Mannheim, Ger-
many). The ATP content of each well was quantified ac-
cording to the amount of ATP-dependent light emitted us-
ing the Victor 3 multi-label counter (PerkinElmer, Boston, 
MA, USA). Raw data in Excel was analyzed with Report 
Maker version 1.1 (ISU ABXIS, Seoul, Korea). Briefly, the 
cell death rate (CDR) for each drug was calculated as fol-
lows: CDR (%)=[1-(mean luminescence in treated group/
mean luminescence in untreated control group)]×100. We 
also calculated the CI as the sum of the percentage cell death 
for all concentrations tested 300‒sum of % inhibition at 
0.2×, 1×, and 5× TDC. The CI rank of the 10 anticancer 
drugs in each cancer tissue was determined according to the 
Table 1. Characteristics of Patients (n=63)
Characteristic n (%)
Median age (range) 52 (22‒71)
Disease status
    Primary epithelial ovarian cancer 41 65.1
    Recurrent epithelial ovarian cancer 15 23.8
    Primary peritoneal cancer   4   6.3
    Recurrent peritoneal cancer   3   4.8
Histologic type
    Serous adenocarcinoma 48 76.2
    Mucinous adenocarcinoma   3   4.8
    Endometrioid adenocarcinoma   7 11.1
    Clear cell carcinoma   2   3.2
    Transitional cell carcinoma   1   1.6
    Epithelioid mesothelioma   1   1.6
    Undifferentiated carcinoma   1   1.6
Tumor grade
    Grade 1   6   9.5
    Grade 2 15 23.8
    Grade 3 17 27.0
    NA 25 39.7
FIGO stage (n=45)
    Stage I   9 20.0
    Stage II   1   2.2
    Stage III 27 60.0
    Stage IV   5 11.1
FIGO, International Federation of Gynecologists and Obstetricians; NA, not 
available.
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ma with marginal statistical significance.
In primary serous adenocarcinoma, ifosfamide was the 
most active drug, followed by paclitaxel, irinotecan, and cis-
platin. Furthermore, ifosfamide was the most active drug in 
mucinous adenocarcinoma, followed by paclitaxel. However, 
in endometrioid adenocarcinoma, irinotecan was the most ac-
tive drug, followed by cisplatin and paclitaxel. In clear cell 
carcinoma, cisplatin and ifosfamide were the most active 
drugs, followed by docetaxel and paclitaxel. For most anti-
cancer drugs, the CIs in clear cell carcinoma and undifferenti-
ated carcinoma were not higher than that of serous adenocar-
cinoma. The CI values for cisplatin, carboplatin, paclitaxel, 
and docetaxel, which are the most commonly used anticancer 
drugs for primary epithelial ovarian cancer, were not higher 
in clear cell carcinoma compared to serous adenocarcino-
ma. The CI according to tumor grade is shown in Table 3. 
of serous adenocarcinoma, especially cisplatin (median CI; 
clear cell: 145; serous: 176; p=0.052) and carboplatin (medi-
an CI; clear cell: 178; serous: 204; p=0.076). These results 
indicate that, at least in vitro, cisplatin and carboplatin may 
be more active against clear cell carcinoma than serous ade-
nocarcinoma. Two taxanes (paclitaxel and docetaxel), three 
camptothecin analogues (topotecan, irinotecan, and belote-
can), and gemcitabine showed no significant differences 
among histological types, with the exception of docetaxel in 
endometrioid adenocarcinoma. Docetaxel showed an in-
creased CI in endometrioid carcinoma compared to that in 
serous adenocarcinoma (median CI; endometrioid: 215; se-
rous: 171; p=0.034). The CIs of topotecan (median CI; clear 
cell: 148; serous: 185; p=0.070) and ifosfamide (median CI; 
clear cell: 122; serous: 174; p=0.074) were lower in clear 
cell carcinoma compared with those in serous adenocarcino-
Table 2. CI by Histologic Type in Primary Ovarian Cancer (n=41) 
Chemotherapeutic  
  agent
CI, median (range)
Serous 
adenocarcinoma 
(n=28)
Mucinous 
adenocarcinoma 
(n=3)
Endometrioid 
adenocarcinoma 
(n=7)
Clear cell carcinoma 
(n=2)
Undifferentiated 
carcinoma 
(n=1)
Cisplatin 176 (113‒244)   198 (173‒223) 174 (65‒215) 145 (113‒176) 161 
Carboplatin 204 (159‒254)   221 (194‒249)   204 (108‒250) 178 (159‒198)   78 
Oxaliplatin 198 (139‒248) NA   188 (187‒189) 164 (139‒188) 256 
Paclitaxel 172 (85‒204) 132 (87‒176)   175 (125‒203) 139 (108‒171)   51 
Docetaxel 190 (132‒249)   184 (176‒192)   224 (150‒254) 172 (137‒207) 193 
Topotecan 185 (111‒241)   180 (175‒184)   204 (115‒248) 148 (118‒178) 300 
Irinotecan 172 (104‒230)   180 (171‒190)   159 (116‒201) 141 (116‒201) 209 
Belotecan 188 (143‒238)   164 (154‒174) 202 (93‒268) 163 (93‒268) 123 
Gemcitabine 249 (188‒285)   258 (219‒297)   249 (168‒291) 260 (256‒263) 286 
Ifosfamide 174 (93‒209) NA   182 (172‒191) 122 (93‒151)   31 
CI, chemosensitivity index; NA, not available. 
Table 3. CI by Tumor Grade in Primary Ovarian Cancer (n=33)
Chemotherapeutic 
  agent
CI, median (range)
p value†
Grade 1 (n=4) Grade 2 (n=13) Grade 3 (n=16)*
Cisplatin 190 (172‒208)   190 (113‒217) 162 (65‒244) 0.074
Carboplatin 224 (199‒250)   207 (159‒254) 200 (78‒254) 0.109
Oxaliplatin NA   187 (139‒204)   212 (155‒256) 0.034
Paclitaxel 176 (140‒189)   175 (108‒204) 160 (51‒201) 0.252
Docetaxel 227 (197‒254)   202 (137‒249)   192 (132‒238) 0.082
Topotecan 211 (192‒232)   179 (118‒242)   190 (111‒300) 0.453
Irinotecan 201 (201‒201)   170 (104‒230)   170 (116‒210) 0.487
Belotecan 190 (146‒268)   202 (143‒224) 172 (93‒238) 0.383
Gemcitabine 274 (209‒291)   249 (188‒283)   249 (168‒286) 0.423
Ifosfamide NA 172 (93‒191) 163 (31‒209) 0.630
CI, chemosensitivity index; NA, not available.
*Undifferentiated carcinoma is included.
†Kruskal-Wallis test.
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platin was higher for recurrent disease (median CI rank: 6) 
compared to that of primary disease (median CI rank: 7).
The median CI values of 2 taxanes (paclitaxel and docetax-
el) were similar in primary and recurrent disease for both pa-
clitaxel (primary: 168; recurrent: 176; p=0.318) and docetax-
el (primary: 190; recurrent: 189; p=0.522). The CI rank of 
paclitaxel was higher in recurrent disease, but the difference 
was not statistically significant (median CI rank; primary: 3; 
recurrent: 2; p=0.491). The CI rank of docetaxel did not 
change in recurrent disease (median CI rank; primary: 5; 
recurrent: 5).
Three camptothecin analogues (topotecan, irinotecan, and 
belotecan) showed decreased CI values in recurrent disease. 
The median CI value in primary or recurrent disease for 
topotecan was 185 and 215, respectively (p=0.049); for iri-
notecan, 171 and 217 (p=0.001); and for belotecan, 183 and 
248 (p=0.008). The median CI rank of topotecan in primary 
and recurrent disease was the same, but irinotecan and be-
lotecan had lower CI ranks in recurrent disease (5 and 6, re-
spectively) compared to those of primary disease (3 and 5, 
respectively) (Fig. 1). The median CI of ifosfamide in pri-
mary and recurrent disease was 165 and 173, respectively 
(p=0.221). The median CI rank of ifosfamide in primary 
and recurrent disease was 2 and 3, respectively.
Although not statistically significant, the CIs of cisplatin, 
carboplatin, and paclitaxel decreased as tumor grade in-
creased. However, oxaliplatin showed an increased CI as 
tumor grade increased (p=0.072). The CI of each chemo-
therapeutic agent in primary or recurrent disease is shown 
in Table 4 and Supplementary Fig. 1 (only online). In recur-
rent disease, the CI (especially of cisplatin, carboplatin, 
topotecan, irinotecan, and belotecan) was higher compared 
to that of primary disease. The CI rank of each anticancer 
drug in primary or recurrent disease is shown in Table 4. In 
primary disease, ifosfamide ranked first, followed by pacli-
taxel and irinotecan. In recurrent disease, paclitaxel ranked 
first, followed by ifosfamide and cisplatin.
Increased CIs in recurrent disease were found for two 
platinum analogues, cisplatin (median CI; primary: 174; re-
current: 220; p=0.001) and carboplatin (median CI; prima-
ry: 201; recurrent: 241; p=0.001). The CI rank of carboplat-
in was lower in recurrent disease (median CI rank; primary: 
7; recurrent: 8; p=0.010), but the CI rank of cisplatin was 
the same in primary and recurrent disease (median CI rank; 
primary: 4; recurrent: 4), as shown in Table 3. The median 
CI values of oxaliplatin in primary and recurrent disease 
were 189 and 200, respectively (p=0.117). In addition to 
the increase seen in recurrent disease, the CI rank of oxali-
Table 4. CI in Primary and Recurrent Disease
Chemotherapeutic 
  agent
Disease status
Patient  
n
CI
p value*
Median Minimum Maximum
Cisplatin
Primary 41 176   65 244 
0.001 
Recurrent 14 223 130 269 
Carboplatin
Primary 41 202   78 255 
0.002 
Recurrent 14 241 185 300 
Oxaliplatin
Primary 21 189 139 256 
0.312 
Recurrent 14 200 131 289 
Paclitaxel
Primary 39 169   51 256 
0.449 
Recurrent 14 181   71 286 
Docetaxel
Primary 40 194 132 254 
0.587 
Recurrent 14 200 127 285 
Topotecan
Primary 40 186 111 300 
0.129 
Recurrent 14 209 145 297 
Irinotecan
Primary 36 172 104 230 
0.003 
Recurrent 14 211 142 285 
Belotecan
Primary 39 183   93 268 
0.016 
Recurrent 12 251   69 276 
Gemcitabine
Primary 40 250 168 297 
0.343 
Recurrent 14 258 216 300 
Ifosfamide
Primary 21 172   31 214 
0.330 
Recurrent 12 181   94 228 
CI, chemosensitivity index.
*Mann-Whitney U test; 2-sided tests. 
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recurrent and primary disease.
The newly developed oxaliplatin showed a slightly de-
creased CI in recurrent disease; however, the CI rank in-
creased in recurrent disease compared with that of other che-
motherapeutic agents.
Three camptothecin analogues, as well as irinotecan and 
belotecan, showed decreased chemosensitivity in recurrent 
disease. In addition, the median CI ranks of irinotecan and 
belotecan were lower in recurrent disease compared with 
that of other chemotherapeutic agents. These results sug-
gest that irinotecan and belotecan may be less effective than 
other chemotherapeutic agents for recurrent disease.
Ifosfamide maintained a high CI rank (median CI rank: 
3) in recurrent disease, and the CI also increased slightly.
Among 10 chemotherapeutic agents, the most effective 
drugs in primary disease were ifosfamide and paclitaxel, 
followed by cisplatin and irinotecan. These results strongly 
suggest that ifosfamide could be a first-line combination 
chemotherapeutic agent for primary disease. Although pa-
clitaxel and platinum combination chemotherapy has been 
used in patients with primary ovarian or peritoneal cancer, 
the addition of ifosfamide may be more effective for prima-
DISCUSSION
The current study examined the CI and CI ranks of 10 che-
motherapeutic agents that are used in the treatment of ovar-
ian and peritoneal cancers. This study showed a trend to-
ward an increased CI in recurrent disease compared with 
those in primary disease for most anticancer drugs. These re-
sults suggest that recurrent disease is more resistant to most 
chemotherapeutic agents than primary disease. In particular, 
two commonly used platinum analogues (cisplatin and car-
boplatin) showed statistically significant increases in CI in re-
current disease. The CI rank of carboplatin was reduced in 
recurrent cases, indicating that recurrent disease becomes 
more resistant to carboplatin than to other chemotherapeutic 
agents. This might be due to previous exposure of patients to 
platinum agents. In contrast to the platinum agents, two tax-
anes (paclitaxel and docetaxel), which are also commonly 
used for primary ovarian cancer, did not show significant 
increases in CI in recurrent disease. Furthermore, the CI 
ranks of paclitaxel and docetaxel did not change in recur-
rent disease, suggesting that taxanes may be effective for 
Fig. 1. Box-and-whisker plots of the CI rank of 10 chemotherapeutic agents in primary (A) and recurrent disease (B). The bottom and top edges of the box rep-
resent the 25th and 75th percentiles, respectively, whereas the horizontal line corresponds to the median value. The vertical lines show the range of values. 
The agents that were ranked with the first and second CI values in primary and recurrent disease were paclitaxel and ifosfamide. CI, chemosensitivity index.
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ing combination may be beneficial as a first-line chemother-
apy regimen for primary and recurrent disease. Therefore, 
we recommend a TIP combination chemotherapy regimen 
for recurrent and primary disease.
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sults suggest that paclitaxel might be the most effective drug 
for recurrent disease, and ifosfamide may be an effective sec-
ond-line chemotherapeutic agent for recurrent disease. As a 
result, the TIP regimen may be considered a second-line op-
tion for platinum-sensitive recurrent disease. Polyzos, et al.19 
reported the activity and toxicity of a paclitaxel-ifosfamide-
cisplatin combination (paclitaxel 175 mg/m2 as a 3-hour IV 
on day 1, cisplatin 75 mg/m2 IV over 2 hours fractionated 
over days 1 and 2, and ifosfamide 5 mg/m2 IV over 1 hour 
fractionated on days 1‒2 with mesna uroprotection, every 3 
weeks) in 35 patients with ovarian cancer previously treated 
with platinum compounds and paclitaxel. In this report, 
three drug combinations demonstrated significant efficacy 
against potentially platinum-sensitive tumors and moderate 
efficacy in platinum-resistant tumors with tolerable myelo-
toxicity levels. 
In the current study, clear cell carcinoma and undifferenti-
ated carcinoma, which usually have poor prognosis, demon-
strated no difference in CI values. These histological types 
showed increased chemosensitivity. Furthermore, high-grade 
disease demonstrated increased sensitivity to most chemo-
therapeutic agents. These results were the opposite of our 
expectation, which was that tumors with poor prognostic 
histological types and grades would be more resistant to 
chemotherapeutic agents.
In conclusion, our study demonstrated that primary or re-
current ovarian and peritoneal cancer tissues were the most 
sensitive to ifosfamide and paclitaxel. Although this was an 
in vitro study, the results suggest that an ifosfamide-contain-
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Supplementary Fig. 1. Box-and-whisker plots of the CI values of 10 chemotherapeutic agents in primary and recurrent disease. The bottom and top edges of 
the box represent the 25th and 75th percentiles, respectively, whereas the horizontal line corresponds to the median value. The vertical lines show the 
range of values. The CI appeared to be higher in recurrent disease than in primary disease for most anticancer drugs. *p<0.05. CI, chemosensitivity index.
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